Shares of Humana Inc. HUM shed 1.82% to $264.58 Friday, on what proved to be an all-around poor trading session for the stock ...

Humana’s (HUM) ongoing litigation with the Center for Medicaid & Medicaid Services on its Medicare Advantage Stars performance remains a ...

Currently, Humana has a poor Growth Score of F, a grade with the same score on the momentum front. However, the stock was allocated a grade of A on the value side, putting it in the top 20% for ...

Humana’s outlook isn’t great, but performance in the fourth quarter ... privately-managed health scheme for older Americans. Humana stock has fallen roughly 40% since the start of 2023 as ...

The company's recent financial performance has been mixed. While Humana has maintained a solid ... HUM appears on our undervalued or overvalued stock lists. These tools provide a clearer picture ...

HUM has been the topic of several other reports. TD Cowen lifted their target price on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a report on Monday, November 4th.

In a report released today, Andrew Mok CFA from Barclays maintained a Hold rating on Humana (HUM – Research Report), with a price target of ...

Humana (HUM) stock is plunging in Wednesday's session ... Sign up "The decline in Stars performance for 2025 will impact Humana's quality bonus payments in 2026," Humana said in the filing.

Nasdaq Dividend History provides straightforward stock’s historical dividends data. Dividend payout record can be used to gauge the company's long-term performance when analyzing individual stocks.

The stock's fall snapped a two-day winning streak.